Paper Details

  1. Home
  2. Paper Details

Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies.

Author: AhnJaeil, CarlsonAlexis, DunnConnell, FalconerRamsey A, HebronMichaeline, HowardHellen, HuangXu, LawlerAbigail, LiZhaoxia, MillsReversa R, MoussaCharbel, PaganFernando, RogersSean L, Torres-YaghiYasar, ValadezEllen H, WilmarthBarbara M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Low doses of Nilotinib were safe and tolerated in patients with advanced Parkinson’s disease. Nilotinib appears to be able to engage the target Abl.
Paper Details　
Original Abstract of the Article :
BACKGROUND: We evaluated the effects of low doses of the tyrosine kinase Abelson (Abl) inhibitor Nilotinib, on safety and pharmacokinetics in Parkinson's disease dementia or dementia with Lewy bodies. OBJECTIVES: The primary outcomes of this study were safety and tolerability; pharmacokinetics and ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008228/

データ提供：米国国立医学図書館（NLM）

Nilotinib: A Potential Oasis for Parkinson's Disease and Dementia with Lewy Bodies?

Parkinson's disease and dementia with Lewy bodies are challenging neurodegenerative conditions. This research explores the potential of Nilotinib, a drug originally developed for cancer treatment, as a potential therapy for these disorders. It's like venturing into a new territory in the desert of neurodegenerative diseases, seeking a potential path to relief.

A Promising New Direction for Neurological Treatment

The study found that Nilotinib appeared to be safe and tolerated in patients with advanced Parkinson's disease, with possible benefits for motor and cognitive function. It's like discovering a new spring in a desert of neurodegeneration – a potential source of hope for a better future. However, this study was small and lacked a placebo control group, so further research is needed to confirm the efficacy of Nilotinib.

Navigating the Uncharted Terrain of Neurological Disease

This research highlights the importance of exploring new avenues for treating neurological diseases. It's a reminder that the desert of neurodegeneration is vast and complex, but with continued research and innovation, we can find new oases of hope for those affected.

Dr.Camel's Conclusion

This study offers a glimpse into the potential of repurposing existing drugs for neurological conditions. While more research is needed to confirm the efficacy of Nilotinib, it represents a promising avenue for exploring innovative therapies for Parkinson's disease and dementia with Lewy bodies. It's a reminder that the desert of scientific discovery is vast and unpredictable, but with perseverance, we can find new solutions to some of the most challenging health problems.

Date :
  1. Date Completed 2017-11-09
  2. Date Revised 2022-01-14
Further Info :

Pubmed ID

27434297

DOI: Digital Object Identifier

PMC5008228

Related Literature

Article Analysis
・Effects of nilotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.